Plain language summary of the IMerge Phase 3 study: imetelstat vs placebo in lower-risk myelodysplastic syndrome patients with anemia

This Plain Language Summary of Publication article (PLSP) from Future Oncology examined Imetelstat, an FDA-approved treatment for patients with lower-risk myelodysplastic syndrome (MDS) who require regular transfusions and haven’t responded to standard therapies. Given intravenously every 4 weeks, it was approved based on positive results from the Phase 3 IMerge trial. MDS are blood cancers causing anemia that leads to fatigue and frequent transfusion needs.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial’ and was published in The Lancet.

Visit Lancet using the link to read the original article.

• anemia
• cytopenias
• ESA-ineligible
• imetelstat
• lay summary
• myelodysplastic syndromes
• plain language summary